QUOTED. May 30, 2018. David Kandzari.
Executive Summary
Positive six-month results – the first-ever data from Medtronic's pilot study of its Symplicity Spyral renal denervation (RDN) system – hold the promise of setting the medtech giant back on track and toward a market opportunity worth billions of dollars. See what the study's principal investigator, David Kandzari, said about it here.
"There are a number of reasons to be excited about these particular data. Hypertension is the leading cause of death and disability worldwide, more than any other disease state and the prevalence of hypertension hasn't changed, it's been relatively stagnant. If anything, [prevalence] has increased but the treatment and control of blood pressure has plateaued and declined so there is an urgent need for alternative therapies for more effective of blood pressure control." –David Kandzari, principal investigator, Piedmont Heart Institute
Click here for a free trial of Medtech Insight